YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017

This table browses all dspace content
Issue Date	Title	Journal Title
2022	A study of the regional differences in propacetamol-related adverse events using VigiBase data of the World Health Organization	SCIENTIFIC REPORTS
2022	A low risk of nosocomial transmission of subclinical tuberculosis to neonates in a postpartum care center under COVID-19 control measures	Osong Public Health and Research Perspectives
2022	국내 의료기관에서 홍역 발생과 전파를 최소화하기 위한 전략	Korean Journal of Healthcare-associated Infection Control and Prevention(의료관련감염관리)
2022	비유두부 십이지장 종양	Korean Journal of Helicobacter and Upper Gastrointestinal Research
2022	대한내과학회가 당면한 과제	Korean Journal of Medicine
2022	Temporal trends in heart failure over 11 years in the aging Korean population: A retrospective study using the national health insurance database	PLOS ONE
2022	대장암 생존자의 암 발생 위치에 따른 배변 관련 삶의 질	ASIAN ONCOLOGY NURSING
2022	A Systematic Review and Meta-Analysis of Clinical Outcomes of Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention	JOURNAL OF INVASIVE CARDIOLOGY
2022	Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma	BLOOD
2022	Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)	ANNALS OF ONCOLOGY
2022	Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL	BLOOD
2022	Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study	BLOOD
2022	MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure	ANNALS OF ONCOLOGY
2022	Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722	ANNALS OF ONCOLOGY
2022	Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis	GUT AND LIVER
2022	Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial	JAMA CARDIOLOGY
2022	Lactobacillus acidophilus KBL409 Reduces Kidney Fibrosis via Immune Modulatory Effects in Mice with Chronic Kidney Disease	MOLECULAR NUTRITION & FOOD RESEARCH
2022	Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis	KOREAN JOURNAL OF INTERNAL MEDICINE
2022	Real-world clinical features, health-care utilization, and economic burden in decompensated cirrhosis patients: A national database	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2022	Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study	ANNALS OF ONCOLOGY